TOKYO, Feb 5, 2026 - (JCN Newswire via SeaPRwire.com) - TANAKA PRECIOUS METAL TECHNOLOGIES Co., Ltd. (Head Office: Chuo-ku, Tokyo; Representative Director & CEO: Koichiro Tanaka), a company engaged in the industrial precious metals business of TANAKA, announced today that it has established a total solution system capable of supporting all processes in the contract manufacturing business for various test kits including in vitro diagnostics.Until now, TANAKA has been responsible primarily for processes from developing and manufacturing test kits to bulk production of extraction buffer. At this time, TANAKA established dedicated production lines for the dispensing and packaging of extraction buffer, creating a system that enables it to complete all processes in-house from development to manufacture of final products. This enables TANAKA to reduce costs and the time for external outsourcing and transportation, making it possible to deliver high-quality products in shorter times.In addition, TANAKA will seek to expand production capacity and shorten lead times even further by introducing additional state-of-the-art automatic assembly lines and extract dispensing equipment with a target of March 2026.TANAKA's Total Solution SystemFlexible responses achieved through reinforced integrated production systemBy establishing this total solution system, TANAKA will be able to provide comprehensive contract services covering all processes from test kit development and manufacturing to bulk production, dispensing, and packaging of extraction buffer. This will enable TANAKA to continuously support customers from the development stage through mass production while also accommodating request for individual processes such as extraction buffer dispensing only.By bringing production processes entirely in-house, TANAKA will further reinforce stable supply and quality control.A track record in the development of diagnostic test kits across a wide range of disease areas and examples of deploymentTANAKA offers in vitro diagnostics for a wide range of infectious diseases including respiratory tract infections, such as influenza and COVID-19, as well as dengue and ZIKA viruses. These test kits are compatible with various sample types such as saliva, blood, and urine, and support rapid and accurate testing in clinical settings.Respiratory Tract InfectionsMosquito-Born Infectious DiseasesObstetrics・ Influenza virus・ Adenovirus・ RS virus・ Human meta-virus・ COVID-19・Group A beta hemolytic Streptococcus (Streptococcus pyogenes)・ Dengue virus・ Zika virus・ Chikungunya virus・ Pregnancy testingExamples of Disease Areas That TANAKA Deploys Tests ForTechnical foundations and future outlookTANAKA started research and development of in vitro diagnostics around 2006 and has accumulated technologies centered on nano-colloidal gold (Au). It possesses a diverse range of technologies that support the enhancement of reagent performance using immunochromatographic assay, including protein immobilization technology, non-specific absorption expression technology, and antigen-antibody reaction enhancement technology, TANAKA provides contract manufacturing of high-quality test kits that leverage these technologies in accordance with the ISO 13485 system.Going forward, TANAKA will leverage this total solution system to develop new diagnostics in collaboration with partner companies, while contributing to solutions to social issues and advancement of the field of medicine.About TANAKASince its foundation in 1885, TANAKA has built a portfolio of products to support a diversified range of business uses focused on precious metals. TANAKA is a leader in Japan regarding the volume of precious metals it handles. Over many years, TANAKA has manufactured and sold precious metal products for industry and provided precious metals in such forms as jewelry and assets. As precious metals specialists, all Group companies in Japan and worldwide collaborate on manufacturing, sales, and technology development to offer a full range of products and services. With 5,591 employees, the group’s consolidated net sales for the fiscal year ended December 2024 were 846.9 billion yen.TANAKA Industrial Precious Metal Materials Portalhttps://tanaka-preciousmetals.comProduct inquiriesTANAKA PRECIOUS METAL TECHNOLOGIES Co., Ltd.https://tanaka-preciousmetals.com/en/inquiries-on-industrial-products/Press inquiriesTANAKA PRECIOUS METAL GROUP Co., Ltd.https://tanaka-preciousmetals.com/en/inquiries-for-media/Press release: https://www.acnnewswire.com/docs/files/20260205_EN.pdf Disclaimer:ANY EXPRESS WRITTEN WARRANTY THAT TANAKA MAY ISSUE, IS THE SOLE AND EXCLUSIVE WARRANTY AS TO TANAKA’S MATERIALS AND PRODUCTS, EXTENDS ONLY TO THE INITIAL PURCHASER FROM TANAKA OR ITS AUTHORIZED DISTRIBUTOR, IS NOT TRANSFERABLE OR ASSIGNABLE, AND IS EXPRESSLY IN LIEU OF AND TANAKA EXPRESSLY DISCLAIMS TO THE EXTENT PERMISSIBLE UNDER APPLICABLE LAW ANY OTHER WARRANTY, ORAL OR IMPLIED, INCLUDING WITHOUT LIMITATION ANY ORAL OR IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR PARTICULAR PURPOSE.TANAKA SHALL NOT BE LIABLE FOR ANY INCIDENTAL, SPECIAL, OR CONSEQUENTIAL LOSS, DAMAGE, OR EXPENSE (INCLUDING, WITHOUT LIMITATION, LOST PROFITS) DIRECTLY OR INDIRECTLY ARISING FROM THE SALE, INABILITY TO SELL, USE, OR LOSS OF USE OF ANY PRODUCT. NO ORAL OR WRITTEN INFORMATION OR ADVICE GIVEN BY TANAKA, ITS EMPLOYEES, DISTRIBUTORS, DEALERS, OR AGENTS SHALL INCREASE THE SCOPE OF ANY WARRANTY OR CREATE ANY NEW WARRANTIES.THE LIMITATIONS AS STATED HEREIN SHALL NOT PRECLUDE ANY LIABILITY WHICH UNDER APPLICABLE PRODUCTS LIABILITY LAW CANNOT LEGALLY BE PRECLUDED BY CONTRACT OR OTHERWISE. NEVER USE THIS TEST KIT AS THE ONLY GUIDE TO MANAGE YOUR CONDITION OR ILLNESS. CONSULT YOUR HEALTHCARE PROVIDER IF YOUR SYMPTOMS PERSIST OR BECOME MORE SEVERE, OR IF YOU ARE CONCERNED AT ANY TIME. Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com
HONG KONG, Feb 5, 2026 - (ACN Newswire via SeaPRwire.com) – According to the disclosure of interests information released by the Hong Kong Stock Exchange, GIC Private Limited made its equity investment in Ascletis Pharma by acquiring 64,128,000shares at a price of HKD12.18per share, involving a total consideration of approximately HKD781.08million (equivalent to approximately USD100.01 million). Following the transaction, GIC's shareholding in Ascletis Pharma amounted to 64,128,000shares, representing a shareholding percentage of 6.42%, marking GIC's initial entry into the company's shareholder base. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
HONG KONG, Feb 5, 2026 - (ACN Newswire via SeaPRwire.com) – Organised by the Hong Kong Trade Development Council (HKTDC), the world’s largest one-stop jewellery marketplace will return in early March under its proven “Two Shows, Two Venues” format. The 12th Hong Kong International Diamond, Gem & Pearl Show will take place from 2 to 6 March at AsiaWorld-Expo and will feature a wide range of jewellery raw materials. Also, the 42nd Hong Kong International Jewellery Show will be held from 4 to 8 March at the Hong Kong Convention and Exhibition Centre and will showcase finished jewellery pieces.Jenny Koo, Deputy Executive Director of the HKTDC, said: “This year’s twin jewellery shows bring together some 4,000 exhibitors from over 40 countries and regions, with 70% coming from outside Hong Kong. Exhibitor participation from Brazil, United Arab Emirates and India has expanded, and Uzbekistan joins for the first time. The HKTDC presents the world’s largest one-stop jewellery marketplace to highlight Hong Kong’s status as an international trade capital and jewellery sourcing hub.”In reviewing the global jewellery market, Hong Kong’s export volume of premium jewellery to ASEAN recorded a 51% increase, while exports to the United Kingdom, Australia and Switzerland grew year-on-year by 36%, 28% and 10% respectively.Over 40 themed pavilions, including a new Hard Pure Gold PavilionThe twin shows attract strong global industry support, with exhibitors participating from over 40 regional and industry pavilions. Participating regions include Chinese Mainland, Taiwan, India, Israel, Korea, Myanmar, Singapore, Sri Lanka, Thailand, Uzbekistan, Belgium, Germany, Italy, Spain, Türkiye, Brazil, Colombia, Mexico and the United States, etc.The World Gold Council debuts the Hard Pure Gold Pavilion, featuring a total of 11 exhibitors from Chinese Mainland, showcasing innovative gold craftsmanship to the global market. The pavilion aims to leverage the fairs as a springboard for international expansion.The Hong Kong Watch Manufacturers Association Ltd will participate as a pavilion for the first time, while the Zhushan Turquoise pavilion from Hubei will also make its debut. Other returning participants include the Tanzanite Foundation, the International Colored Gemstone Association (ICA), the Asia Pacific Creator Association, and the Asia Jewellery Culture Design and Crafts Association. The Hong Kong Jewellery & Jade Manufacturers Association will once again join forces with the Italian Exhibition Group (IEG) to present advanced jewellery manufacturing equipment and technologies.International brands in the spotlightThe Hall of Fame at the Hong Kong International Jewellery Show makes a highly anticipated return this year with more than 40% expansion in scale. It will welcome renowned international jewellery brands and help enhance global brand exposure. Turkish diamond jewellery brand Zen Diamond (Booth: CEC 3B-C12) presents diamond ring collections featuring exquisite cutting techniques. At the Hall of Extraordinary, Hong Kong exhibitor Continental Diamond Company (Booth: CEC GH-C07) showcases an 18K white and rose gold ring set with blue and light pink diamonds. Another Hong Kong exhibitor, Unique Brilliant Ltd (Booth: CEC GH-C13), unveils a necklace and earring set, the rubies display the coveted “pigeon blood red” colour.Oriental Aesthetics showcases cultural heritage craftsmanshipThis year’s shows will feature numerous jewellery pieces inspired by Asian culture and heritage. Chinese Mainland exhibitor, Guangdong JIABAO Pavilion Jewellery (Hong Kong) Company Ltd (Booth: CEC GH-A16) presents an 18K gold, handmade filigree butterfly brooch, made with national intangible heritage craft, with each piece taking over four months to complete. Another Chinese Mainland exhibitor, Shenzhen Meifei Precious Metals Co Ltd (Booth: CEC 3E-E02), brings a “Palatial Modern Chinese Style” jewellery series incorporating six traditional gold techniques, blending heritage craftsmanship with modern jewellery design.In recent years, hard pure gold technology has gained strong momentum in Chinese Mainland. Its high purity and enhanced hardness enable lighter, more durable designs with modern aesthetics. A seminar organised by the World Gold Council will examine the latest developments in the global gold market and hard pure gold technology.During the fairs, a series of events spotlighting Oriental aesthetics in jewellery will be staged. Hong Kong International Fashion Chuk Kam Jewellery Design Competition 2026, organised by the Jewellers’ and Goldsmiths’ Association of Hong Kong Limited, encourages designers to create commercially viable and culturally rich gold jewellery for young consumer markets in ASEAN and the Middle East. Its award presentation ceremony will be held during the fairs.In addition, the inaugural International Fei Cui Jewellery Design Competition 2026, organised by the Hong Kong Jade Association, will also host its awards presentation during the fairs.Creative design sets the trendInnovative and trend-driven products help the industry stand out. Austy Lee Company Ltd (Booth: CEC 1E-F32) introduces bangles inspired by zebra patterns for the Year of the Horse. Designer Galleria welcomes new exhibitor Zheng Hong Collective (Booth: CEC 1CON-067A), featuring a brooch whose movable wings and tail sway with the wearer.The 27th Hong Kong Jewellery Design Competition, themed “Pure Elegance – Natural Beauty”, returns to nurture creative talent. Local students and industry professionals interpret the beauty of nature and their design stories through their creations, highlighting the diverse facets of jewellery design. Winning designs will be announced during the fairs.Rare treasures dazzle across both showsAs always, the twin shows offer buyers an outstanding selection of antique and rare jewellery. At the Hong Kong International Jewellery Show, Hong Kong exhibitor Baroque Antique & Jewellery Limited (Booth: CEC CH-F13) presents a 1970s Buccellati pink sapphire suite, while World Coins Co., Ltd. (Booth: CEC CH-N12) showcases a 19th-century Italian bi-colour enamel diamond piece preserved in its original box for over 100 years. At the Hong Kong International Diamond, Gem & Pearl Show, German exhibitor Caram e.K. (Booth: AWE 8-F05) features an 18.98-carat AGL-certified natural pink sapphire, while Canadian exhibitor Korite Ammolite Ltd. (Booth: AWE 8-F35) displays an 18K gold AA-grade ammolite and diamond necklace.The Hong Kong International Jewellery Show will also host a seminar titled “The Origins of Style: Tracing the Imprint of Time and Craftsmanship.” This seminar will invite British historian and jewellery authority Dr. Jack Ogden to speak. He will provide an in-depth analysis of the evolution of jewellery craftsmanship and changes in aesthetic tastes across different eras.Over 20 forums on hot topics including AI and digital marketingMore than 20 seminars and networking sessions will be held, covering industry trends, digital marketing and jewellery technologies. A session will examine how artificial intelligence moves from design to commercialisation to drive the development of the jewellery industry. There will also be seminars where influencers share how to leverage e-commerce platforms to enhance jewellery brand visibility, boost sales, and share practical experience, to help the industry accelerate the integration and synergy between online and offline channels.Business opportunities and industry exchangeThe exhibition attracts major international jewellery retail chains, as well as high-end, affordable luxury, and designer jewellery brands from around the world for sourcing. It creates business opportunities for both buyers and sellers while fostering industry exchange.The HKTDC has partnered with the Hong Kong Tourism Board and local enterprises to provide exclusive buyer privileges. These offers include dining, air tickets, and hotels, enabling buyers to enjoy Hong Kong’s unique charm while attending the fairs. The HKTDC will arrange free shuttle bus services between AsiaWorld-Expo and urban areas (including the Hong Kong Convention and Exhibition Centre in Wan Chai). For details, please refer to the fair’s official website.Combining online and offline services to facilitate sourcingThe shows use the EXHIBITION+ hybrid format. In addition to on-site procurement, the HKTDC’s AI-powered “Click2Match” will provide online business-matching for exhibitors and buyers from 23 February to 13 March. On-site buyers can use "Scan2Match" to scan exhibitors’ QR codes and continue discussions with exhibitors online during or after the show. To ease the buyer admission process, the HKTDC Marketplace App and the official websites of the two shows provide online verification functions. Buyers need only register through these platforms and upload a photo and valid identification to obtain a verified eBadge for direct entry, greatly reducing queuing times for onsite registration and verification and enhancing sourcing efficiency.Photo download: https://bit.ly/4ayrcAoAttending the press conference to introduce the twin jewellery shows today (5 February): Jenny Koo, HKTDC Deputy Executive Director (centre), Winston Chow, Chairman, HKTDC Jewellery Advisory Committee (left) and Kent Wong, Chairman, HKTDC Hong Kong International Jewellery Show and HKTDC Hong Kong International Diamond, Gem and Pearl Show Fair Organising Committee (right)Jenny Koo (front row, third left) took a group photo with members of the organising committee of the HKTDC Hong Kong International Jewellery Show and the Hong Kong International Diamond, Gem and Pearl Show, joined by celebrity guestArtist Hera Chan (third right) led a group of models to exhibit exquisite jewellery pieces from the showsArtist Hera Chan wore a natural Myanmar jadeite set presented by exhibitor On Tung Company. The exquisite ensemble featured a translucent emerald green jadeite and diamond necklace, ring, and earrings, showcasing a regal and graceful designThe phoenix features in traditional Chinese wedding jewellery, symbolizes auspiciousness and good fortune. Exhibitor Lao Feng Xiang Jewellery Hong Kong Limited presented a "China chic" wedding collection imbued with Oriental charm, crafting accessories that embody the imperial elegance of a royal court for womenWebsites Hong Kong International Jewellery ShowExhibition websitehttp://hkjewelleryshow.hktdc.com/tcShuttle bus detailshttps://www.hktdc.com/event/hkjewellery/tc/travel-to-fairground-hkcecActivity listhttps://www.hktdc.com/event/hkjewellery/tc/intelligence-hub Hong Kong International Diamond, Gem & Pearl ShowExhibition websitehttp://hkdgp.hktdc.com/tcShuttle bus detailshttps://www.hktdc.com/event/hkdgp/tc/travel-to-fairground-aweActivity listhttps://www.hktdc.com/event/hkdgp/tc/intelligence-hubHKTDC Media Room: https://mediaroom.hktdc.com/enMedia enquiriesPlease contact HKTDC’s Communication & Public Affairs Department:Winnie KanTel: (852) 2584 4055Email: winnie.wy.kan@hktdc.orgKaty WongTel: (852) 2584 4524Email: katy.ky.wong@hktdc.orgJane CheungTel: (852) 2584 4137Email: jane.mh.cheung@hktdc.orgAbout HKTDCThe Hong Kong Trade Development Council (HKTDC) is a statutory body established in 1966 to promote, assist and develop Hong Kong's trade. With over 50 offices globally, including 13 in Chinese Mainland, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitions, conferences and business missions to create business opportunities for companies, particularly small and medium-sized enterprises (SMEs), in the mainland and international markets. The HKTDC also provides up-to-date market insights and product information via research reports and digital news channels. For more information, please visit: www.hktdc.com/aboutus. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
HONG KONG, Feb 5, 2026 - (ACN Newswire via SeaPRwire.com) – Banle Group (“Banle” or the “Group”), a leading Asia-Pacific marine fuel logistics provider, hosted its landmark inaugural ESG Forum — "Charting the New Horizon: Powering Green Shipping with Sustainable Fuels" — uniting top maritime executives, financiers, legal experts, and climate scientists to address the shipping industry's urgent decarbonization challenges on February 2.Speaker Lineup Tackles Critical IssuesThe forum featured exclusive insights from:Dr. Teck Lim Chia, Chairman and CEO of Banle GroupMs. Karen Cheah Yee-Lynn, Independent Director of Banle Group, Partner of Chooi & Company, Immediate Past President of the Malaysian Bar and EXCO Member of LAWASIAMr.Matt Liu Ming-Hsuan, SVP Capital Solutions, Cathay United BankDr.Wilson Cheung Wai-yin, Polar Explorer, Glaciologist and Policy Advisor, Polar Research and Expedition ConsultancyMs.Rebecca Zhang, Senior Manager Sustainable Finance, Commercial Banking, Hong Kong, HSBCThe forum served as a dynamic platform for thought leadership and dialogue, featuring a series of presentations addressing critical topics such as the impact of climate change on global shipping, evolving sustainability-related regulations, and innovative green and sustainability-linked financing solutions.Dr.Teck Lim Chia addressed in the keynote speech, “The global shipping industry stands at a pivotal moment. Rapid regulatory changes, geopolitical tensions, climate challenges, and technological advancements are reshaping the landscape at unprecedented speed. Yet, we are dedicated to fostering a collaborative environment where stakeholders can come together to share insights and develop strategies for a more sustainable future.”On the forum, Ms.Karen Cheah talked about how ESG has become a legal, economic, and moral imperative to safeguard planetary health – and how governments, businesses, courts, and capital markets at an international level must work together holistically to turn sustainability from aspiration into measurable action. She said, “We must establish planetary health metrics to track environmental, health, and risk impacts on all of us. This requires not only a measurement to gauge our progress but also a strategic plan to communicate these metrics, drive global awareness, and educate society at large. Moreover, we must integrate these metrics into governance structures at organizational, domestic, national, and international levels. We must engage in responsible business practices aligned with ESG components and ensure a robust framework for planetary health is implemented globally. Once we align collectively, we can systemize this framework for lasting impact.”Mr.Matt Liu shared his insight on integrating ESG features into financing strategies, “Green loans excel when companies have a clear, specific investment plan. Sustainability-Linked Loans (SLLs) operate under a distinct logic: their Key Performance Indicators (KPIs) must reflect material sustainability issues, be measurable, traceable, and independently verifiable. Crucially, Sustainability Performance Targets (SPTs) must balance ambition with feasibility, remaining achievable within the company’s operational capacity. Unlike green loans, SLLs do not restrict proceeds to green activities; instead, they demonstrate sustainability commitment through performance-linked financial mechanisms. Beyond loans and bonds, nearly all liability-style financial products can now integrate green or sustainability elements. This flexibility allows companies to align financing with sustainability goals while maintaining operational practicality, driving both environmental progress and financial innovation.”Dr.Wilson Cheung addressed his dedication to geoscientific education and advocacy, and talked about the responsible opportunities for the shipping industry, “Responsible opportunities in the shipping industry begin with recognising that the Arctic is not only a shortcut, but also a living homeland and a fragile climate regulator for the planet. New polar sea routes can reduce transit time and fuel use, yet they cross waters where infrastructure is scarce, ecosystems are vulnerable, and Indigenous communities depend on sea ice for culture and survival. True leadership means investing in cleaner fuels, ice-class vessels, and robust search-and-rescue capacity, while strictly limiting black carbon emissions and respecting international polar regulations. It also means listening to local knowledge that has guided safe travel on ice for thousands of years and integrating that wisdom with modern science and satellite data. If the industry embeds ESG principles into every Arctic voyage, these emerging routes can become a model of responsible innovation rather than a new frontier of unchecked risk.”Ms.Rebecca Zhang shared recent shipping industry transition trends from a sustainable finance perspective: “Regulations are constantly evolving, and so must global efforts to tackle climate change and make maritime transport more sustainable. Innovative solutions are emerging, and shipowners are exploring alternative energy options such as biofuels, bio-LNG, and bio-gas. The development of clean technologies is accelerating the industry’s systemic shift towards sustainability.”The forum concluded with a lively and interactive networking among participants, who exchanged ideas and reaffirmed their collective commitment to advancing sustainable practices throughout the shipping industry.Banle Group's sustainability leadership by example through its operational practices was prominently showcased, highlighting its ongoing efforts to spearhead industry decarbonization and responsible practices. Through initiatives like its participation in the EcoVadis rating system and advocacy for diverse sustainable marine fuels, Banle continues to drive meaningful transformation across the shipping sector.Looking ahead, the Banle Group remains committed to hosting future forums that foster dialogue, innovation, and collaboration for a more sustainable maritime ecosystem.Dr.Teck Lim Chia added: "This is just the beginning. Banle will continue driving practical decarbonization solutions for our industry and clients."For more information about Banle Group and its sustainability initiatives, please visit www.banle-intl.com.Photo Caption 1: Dr. Teck Lim Chia (centre) presented souvenirs to all speakers and panelists as a token of appreciation.Photo Caption 2: Panelists engaged in a discussion on the theme: “Charting the New Horizon: Powering Green Shipping with Sustainable Fuels”. Ms. Karen Cheah (left) served as moderator, guiding the discussion while also contributing her insights as a panelist.Photo caption 3: Attendees gathered at the ESG Forum, showcasing a shared commitment to sustainable practices and innovative solutions in the shipping industry.About Banle GroupCBL International Limited (Nasdaq: BANL) is the listing vehicle of Banle Group, a reputable marine fuel logistics company based in the Asia Pacific region that was established in 2015. We are committed to providing customers with a one-stop solution for vessel refueling, which is referred to as bunkering facilitator in the bunkering industry. We facilitate vessel refueling mainly through local physical suppliers in 65 major ports covering Belgium, China, Hong Kong, India, Japan, Korea, Malaysia, Mauritius, Panama, the Philippines, Singapore, Taiwan, Thailand, Turkey and Vietnam. The Group actively promotes the use of sustainable fuels and has been awarded the ISCC EU and ISCC Plus certifications, as well as EcoVadis Silver Medal.For more information, please visit: https://www.banle-intl.com. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
香港, 2026年2月5日 - (亚太商讯 via SeaPRwire.com) - 随著居民健康消费意识持续提高和消费升级，中国私立医疗服务市场，特别是私立中高端医疗服务机构迎来发展窗口。 其中，卓正医疗控股有限公司（"卓正医疗"，股份代号：2677.HK）以独特的家庭医疗模式为核心，融合全科室服务覆盖与线上线下一体化体验，深耕中高端市场多年，已成长为行业领先企业之一。2月3日，卓正医疗结束港股招股，发售价定为66.60港元，预计于2月6日正式登陆港交所。招股期间，公司市场认购热情持续高涨，据富途公开数据显示，其孖展认购额高达665.29亿港元，约超购2103.31倍，成为近期港股市场中备受追捧、认购火爆的新股，机构与个人投资者踊跃布局，用实际行动彰显对公司商业模式、行业地位及未来增长前景的坚定信心。从"个人诊疗"到"家庭入口"：平台化生态铸就增长基石在中高端健康服务赛道竞争日趋激烈的当下，卓正医疗跳出传统医疗机构的发展模式，以家庭为核心深耕高价值会员体系，打造独树一帜的"超级用户"生态，实现复购率与忠诚度双双领跑行业，构筑起坚实的品牌与市场壁垒。不同于传统医疗机构单人单次的低频消费模式，卓正医疗通过整合儿科、齿科、眼科、皮肤科、内科及妇科等超过六大核心专科，为同一家庭的不同成员提供一站式、跨生命周期的健康解决方案，让自身从一个解决特定健康问题的"站点"，转变为一个家庭健康管理的"总入口"和决策中心。当单一家庭成员获得信任并建立服务关系后，带动其他家庭成员自然导入，实现了客户基础的有机扩张和消费场景的极大延伸。这种平台化生态显著提升了客户生命周期价值，推动公司收入持续增长。在"家庭入口"的平台上，卓正医疗进一步通过"卓正会员计划"深化用户关系，将平台流量高效转化为长期、高粘性的"超级用户"。该计划为家庭提供优先预约、专属套餐等权益，不仅提升了服务体验，更在心理层面建立了"健康管家"式的信任纽带，持续提升用户粘性。截至2025年8月31日，公司已拥有超过11.6万个会员帐户，会员续费率达67%，而整体患者回头率高达82.7%，印证了其服务模式强大的客户锁定能力。财务表现逆势增长 数字化 AI 化重塑服务新范式凭借独特的商业模式与高效的运营管理，卓正医疗在医疗服务行业部分机构面临盈利压力的背景下，实现了收入与利润的双重逆势增长。数据显示，2022年至2024 年，卓正医疗营收从4.7亿元增长至9.6亿元，复合年增长率达42.3%，营收规模实现翻倍增长；毛利从4398万元跃升至2.3亿元，复合年增长率高达126.7%，盈利能力大幅提升；2024年，公司更是成功扭亏为盈，经调整净利润1,070万元，实现了从规模增长到盈利增长的质的飞跃。尤为难得的是，卓正医疗的业绩增长并非依赖医保加持或高额营销投入，其营销费用占收比常年维持在2%上下，真正依靠口碑获客实现可持续增长，这种健康的盈利模式也成为资本市场看好公司的重要原因。而数字化与AI技术的深度应用，则为卓正医疗提升运营效率、打造高粘性健康服务生态提供进一步助力。公司自主搭建了HMS医院管理系统、DMS卓正管理系统、卓正数据中台等数字化平台，实现集中化、标准化及数字化的管理，不仅大幅提升医护人员的运营效率，更让用户享受到便捷、高效的诊疗体验，进一步提升了用户满意度。此次港股IPO，卓正医疗计划将把募资净额的35%用于医疗人工智能应用的人才培养、技术研发与外部合作，旨在通过AI技术赋能，革新医疗服务提供方式与运营效率。未来，随著AI技术与医疗服务的深度融合，卓正医疗有望进一步优化使用者体验，提升服务效率，让数字化、智能化成为公司持续增长的新引擎。从千亿健康消费赛道的稀缺标的，到认购火爆的港股IPO新星，卓正医疗的资本市场之路，是其多年深耕高价值健康服务、坚持质量与口碑的必然结果。凭借高复购高忠诚的超级用户生态，公司构筑了行业领先的商业模式壁垒；逆势增长的财务表现，印证了其盈利模式的可持续性；借助数字化与AI化的前瞻布局，公司有望打造了高粘性的健康服务新范式，为长期增长注入强劲动力。在资本赋能下，公司有望进一步夯实自身在中高端健康服务赛道的龙头地位，其上市后的表现，值得长期关注。 Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com
BRISBANE, AUS, Feb 5, 2026 - (ACN Newswire via SeaPRwire.com) - Annature, Australia's leading eSignature and Identity verification provider, has announced the release of its 21 CFR Part 11 compliant electronic signature module, enabling organisations operating in FDA‑regulated environments to execute electronic records with confidence.The new capability ensures Annature customers can meet the U.S. Food and Drug Administration's requirements for electronic records and electronic signatures under 21 CFR Part 11, a regulation that governs data integrity, signer authentication, and auditability across industries such as life sciences, pharmaceuticals, biotechnology, and clinical research.The release has been driven by growing demand from U.S.-based and multinational organisations seeking a modern, compliant alternative to legacy eSignature platforms. Several customers operating in regulated environments have already transitioned to Annature as part of broader digital transformation initiatives, prompting the company to formally introduce Part 11 support as part of its international product roadmap."As we continue to grow globally, it's critical that Annature supports the regulatory frameworks our customers operate under," said Corey Cacic, CEO of Annature. "Our 21 CFR Part 11 module allows organisations subject to FDA requirements to use Annature with confidence, knowing their electronic signatures meet the necessary compliance standards."The module introduces controls aligned with Part 11 expectations, including secure signer authentication, tamper‑evident audit trails, and strong linkage between electronic signatures and the records they relate to. These features ensure electronic signatures executed through Annature can be relied upon in regulated workflows and during regulatory review.Kim Steel, Founder and Managing Director of SAPRO - a boutique CRO supporting niche biotech and pharmaceutical companies with commercially sponsored Phase I-III full-service clinical trials has welcomed the release."For organisations operating in regulated environments, compliance with 21 CFR Part 11 is not optional - it is fundamental," said Steel. "It is encouraging to see Annature, an Australian technology provider supporting international regulatory requirements that are critical to our industry and our clients. Solutions like this enable sponsors to operate confidently on a global stage, without reliance on outdated or overly complex legacy systems, while remaining inspection and audit-ready at all times."The launch further strengthens Annature's position as a global‑ready eSignature platform, supporting organisations that operate across jurisdictions with varying compliance obligations. The 21 CFR Part 11 module is available now and can be enabled for customers who require FDA‑compliant electronic signatures.About AnnatureAnnature is Australia's leading eSignature and Identity verification provider, trusted by over 6,700 businesses. With a Pay as you go model and deep integration across the business app ecosystem, Annature delivers secure, affordable, and locally supported solutions for professionals across the country. Annature's growing product suite also includes integrated payments and compliance features designed to support both domestic and international regulatory requirements.https://www.annature.com.auCONTACT:Name: Corey CacicEmail: corey@annature.com.auSOURCE: Annature Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
MORTSEL, BE, Feb 5, 2026 - (ACN Newswire via SeaPRwire.com) - AGFA HealthCare today announced that it has been named Best in KLAS® 2026 across three Enterprise Imaging segments in the United States, with two awards earned for the second consecutive year, underscoring the company's continued leadership in delivering clinician-first imaging solutions trusted by healthcare organizations worldwide.The recognition comes as KLAS Research marks its 30th anniversary, celebrating three decades of amplifying the voice of healthcare providers through independent, data-driven insights.AGFA HealthCare's Best in KLAS distinctions reflect strong customer validation of its Enterprise Imaging platform - designed to empower clinicians to stay in their flow, reduce complexity across imaging workflows, and enable confident clinical decision-making through connected, high-performing access to images and data.Best in KLAS® - Enterprise Imaging (United States)Enterprise Imaging for Radiology: ranked #1 with a 93.2% score in the PACS (Small - under 300k studies) segment.XERO® Viewer: ranked #1 with a 92.1% score in the Universal Viewer (Imaging) segment for the third consecutive yearEnterprise Imaging VNA: ranked #1 with a 89.8% score in the Vendor Neutral Archive (VNA) segment for the second consecutive year."Being recognized across three Enterprise Imaging segments - including multiple consecutive wins - is a powerful affirmation of our clinician-first strategy," said Nathalie McCaughley, President of AGFA HealthCare. "Healthcare organizations trust us to deliver imaging environments that truly support clinicians in their daily work, while enabling IT and clinical leaders to operate with confidence, performance, and long-term vision. This recognition reflects the strength of our partnerships and our unwavering focus on empowering care teams through connected, intelligent imaging."Commenting on the awards, Adam Gale, CEO of KLAS Research, said:"The Best in KLAS winners have earned the trust of their customers over the past year. With this recognition, they set the standard for excellence through partnership in healthcare technology and services in the months to come."Monique Rasband, Global Vice President of Imaging at KLAS Research, added:"AGFA HealthCare's strong performance across multiple Enterprise Imaging segments reflects consistent customer feedback. Organizations recognize the value of solutions that help imaging teams work efficiently today while providing a clear path for future growth and innovation."The Best in KLAS awards are based on direct feedback from healthcare providers and recognize vendors who consistently demonstrate excellence through partnership, performance, and responsiveness to customer needs.AGFA HealthCare will celebrate its Best in KLAS recognition during HIMSS 2026, alongside customers and partners, as part of its continued commitment to advancing connected, intelligent, and human-centered imaging at scale.KLAS referencesBest in KLAS Awards overview: 2026 Best in KLAS Awards: Software and Services ReportEnterprise Imaging segments reports: 2026 Best in KLAS Awards: Software and Services ReportAbout AGFA HealthCareAt AGFA HealthCare, we understand that striking the critical balance between clinical efficiency and quality patient care starts with the clinician experience. We recognize how vital it is for clinicians to be fully immersed in their cases, channeling all their energy into delivering confident, informed diagnoses. That's why we designed our Enterprise Imaging platform to eliminate the barriers that get in the way. When distractions melt away, technology feels like an extension of one's thought process, and each clinician has everything they need to perform at the top of their craft. That's life in flow.This belief shapes everything we do - guided by our Mission, Vision, and Customer Delivery Principles, which are designed to empower clinicians and elevate their experience.AGFA HealthCare is a division of the Agfa-Gevaert Group. For more information on AGFA HealthCare, please visit www.agfahealthcare.comand follow us on LinkedIn.AGFA and the Agfa rhombus are registered trademarks of Agfa-Gevaert N.V. Belgium or its affiliates. XERO is a registered trademark of Agfa HealthCare N.V. Belgium or its affiliates. All information contained herein is intended for guidance purposes only, and the characteristics of the products and services described in this publication can be changed at any time without notice. Products and services may not be available for your local area. Please contact your local sales representative for availability information. AGFA HealthCare diligently strives to provide as accurate information as possible but shall not be responsible for any typographical error.About KLAS ResearchKLAS Research is a leading healthcare IT data and insights company dedicated to improving global healthcare delivery by amplifying the voice of healthcare providers. Celebrating its 30th anniversary in 2026, KLAS evaluates vendor performance through independent research based on direct customer feedback.Best in KLAS® is a registered trademark of KLAS Research.Press Contact: Jessica Baldry, Global Marketing & Communications Manager, AGFA HealthCare +44 1206 413052 jessica.baldry@agfa.comSOURCE: Agfa HealthCare Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
HONG KONG, Feb 4, 2026 - (ACN Newswire via SeaPRwire.com) – NEW YORK, TAIPEI and TOKYO, Goldenstone Acquisition Limited (Ticker: GDST) (“Goldenstone”), a special purpose acquisition company listed in the U.S. capital market, today announced the execution of a letter of intent (LOI) for a proposed business combination with Deluxe Technology Group (“Deluxe”), a Taiwan-based leader in green technology machinery and sustainable material solutions. The merger is poised to capitalize on the rapidly growing sustainable packaging market, which is projected to reach over $250 billion by 2035.Amidst a complex global regulatory landscape and increasing consumer demand for eco-friendly products, Deluxe has distinguished itself by developing a proprietary and vertically integrated business model. The company’s patented pulp molding formula as well as technology, and use of agricultural waste as a raw material directly address the industry’s most pressing challenges: cost, performance, and scalability. This strategic approach has allowed Deluxe to achieve a significant breakthrough without geographical boundaries by offering compostable product lines that are not only environmentally superior but also cost-competitive with traditional plastics.“Deluxe Technology Group is not just participating in the green transition; they are leading it,” said the CEO of Goldenstone Acquisition Limited. “In a market where many companies struggle with the high cost and inconsistent supply of sustainable materials, Deluxe has created a scalable and economically viable solution. Their ability to turn agricultural waste into high-performance, cost-effective packaging is a game-changer for the industry. We are confident that this merger will unlock significant value for our investors and accelerate the global adoption of sustainable packaging.”The proposed merger is further strengthened by a strategic partnership with Oji Holdings Corporation (“Oji”), a Japanese pulp and paper manufacturing leader. This collaboration secures a stable supply of high-quality raw materials for Deluxe, mitigating a key risk that has hindered the growth of many other sustainable packaging companies. The partnership aligns with Oji’s commitment to contribute the “Harmony with Nature and Society” and will leverage Deluxe’s advanced technology to expand its global footprint.Deluxe’s forward-thinking strategy is also reflected in its recent expansion into the United States, establishing a physical presence to better serve its North American customer base, which includes several Fortune 500 companies. This move is particularly timely, as the North American compostable packaging market represented the largest share in 2025, at around 30% of the global market.“Our mission has always been to prove that sustainability and profitability can go hand in hand,” said Jason Lai, Founder and CEO of Deluxe Technology Group. “With over 130 patents and 20 global awards, our technology is a testament to this vision. By partnering with Goldenstone, we are gaining a strategic partner that will help us to navigate the public markets and to scale our solutions to meet the growing demand from the world’s largest brands. Together, we will accelerate the transition away from single-use plastics and create a more sustainable future.”Under the terms of the LOI, Goldenstone and Deluxe will work exclusively towards the negotiation and execution of a definitive merger agreement. The transaction is subject to due diligence, the execution of definitive agreements, and customary closing conditions, including regulatory and shareholder approvals. The proposed merger aims for a completion and subsequent public listing on the NASDAQ in 2026.Advisors and UnderwritersLoeb & Loeb LLP is serving as legal counsel to Goldenstone Acquisition Limited. MarcumAsia is serving as the Company’s auditor. Maxim Group LLC is acting as the financial advisor for the transaction. Chi Advisory Limited is serving as a financial advisor to Deluxe.About Goldenstone Acquisition Limited (Ticker: GDST)Goldenstone Acquisition Limited is a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. Goldenstone Acquisition Limited completed its US$57.5 million initial public offering on March 17, 2022, with about US$5.3M trust account balance as of September 30, 2025.About Oji Holdings Corporation (TYO: 3861)Oji is a leading Japanese company committed to resource sustainability and industrial innovation. Grounded in their philosophy to contribute to the "Creation of Innovative Value" and "Harmony with Nature and Society," Oji serves as both a strategic investor and a primary supplier of premium pure pulp to Deluxe, facilitating global expansion and environmental stewardship.About Deluxe Technology GroupHeadquartered in Taiwan with operations expanding into the US, Deluxe Technology Group is a premier provider of green technology machinery and sustainable product solutions. Specializing in pulp molding formula and ESG Technology, the company offers a complete turnkey solution. With over 20 global awards, and more than 130 patents, Deluxe provides compostable alternatives to plastic that are produced with industry-leading energy efficiency, with select products offering superior cost-competitiveness to plastic. Deluxe is supported by a prestigious consortium of institutional investors, validating Deluxe’s potential to lead the global green transition. Key investors include GIC (Government of Singapore Investment Corporation), Sigma Global Fund, JAFCO Asia, Oji Holdings Corporation, SBI & Capital 22, Cathay Private Equity, and Delta Electronics.Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. This includes statements regarding the intent to enter into a definitive agreement and the timeline for a 2026 merger. These statements are based on various assumptions and the current expectations of the management of Goldenstone and Deluxe and are not predictions of actual performance. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of Goldenstone and Deluxe.No Offer or SolicitationThis press release shall not constitute a solicitation of a proxy, consent, or authorization with respect to any securities or in respect of the proposed business combination. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction where such offer, solicitation, or sale would be unlawful under the securities laws of any such jurisdiction.Contact Information:Investor Relations: Goldenstone Acquisition Limited Email: eddie@windfallusa.comEmail: ir@chi-am.comMedia Contact: Deluxe Technology GroupEmail: media@deluxe-tech.com Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
OSAKA, Japan, Feb 5, 2026 - (ACN Newswire via SeaPRwire.com) – February 4, 2026, SuperX Industries Co., Ltd. ("SuperX"), a Japanese subsidiary of SuperX AI Technology Limited (“NASDAQ:SUPX”), today announced the signing of an Memorandum of Understanding ("MOU") on February 4, 2026 with Digital Dynamic Inc. ("DD"), eole Inc. ("eole"), and Woodman Inc. ("Woodman"). This MOU builds on the parties’ prior cooperation to establish a comprehensive framework for the co-development of large-scale AI Data Centers (AIDC) across Japan.Advancing the Mie Prefecture Pilot ProjectFollowing the first MOU signed on January 30, 2026 in Osaka, Japan, the Parties entered into the MOU to further deepen collaboration by establishing a joint task force to pilot an AIDC project in Mie Prefecture, Japan with an initial facility capacity up to 4MW, subject to feasibility assessments, site conditions, regulatory approvals, and the execution of definitive agreements. The pilot initiative is intended to serve as a starting point for assessing potential future expansion up to 300MW in total capacity.Addressing Japan’s AI Infrastructure BottleneckThe shift toward modular architecture directly addresses Japan’s growing demand for the expansion of domestic AI capacity on an accelerated timeline. Unlike traditional "brick-and-mortar" builds that can take years to complete, SuperX’s modular approach accelerates deployment by reducing construction timelines significantly. This new pilot project is designed to be purpose-built for next-generation, liquid-cooled GPUs—capabilities often lacking in legacy data centers.Scalable delivery and reliable operationsPursuant to the MOU, the Parties intend to collaborate on the system-level integration of critical infrastructure, including advanced power systems and liquid cooling solutions essential for continuous AI workloads. The framework also contemplates the future integration of renewable energy components, such as solar and wind power, energy storage systems, and grid interconnection, subject to site conditions, commercial viability and regulatory approvals.To facilitate execution, a joint task force is expected to be established to define technical architecture, governance, and near-term milestones. SuperX will lead the provision of the modular system architecture and power system integration.Executive quote“Speed-to-market is the new currency in the AI race,” said Aiko Furukawa, the CEO of SuperX Industries Co. Limited. “This pilot project in Mie Prefecture is intended to demonstrate how we can deploy AI infrastructure with speed. Alongside our partners, we aim to demonstrate that modular scalability is the most viable path to meeting Japan's surging demand for AI.”Looking aheadLooking forward, the Parties intend to use the initial pilot as a reference framework to evaluate broader modular AIDC opportunities across Japan, including scalable pathways for expansion—subject to further feasibility assessments, regulatory approvals, site conditions, and the negotiation and execution of definitive agreements.About Digital Dynamic IncDigital Dynamic Inc. is one of Japan’s fastest-growing AI infrastructure operators, with a rapidly expanding deployment of NVIDIA-based inference GPU resources. In 2026, the company plans to complete AI data centers in Kagoshima Prefecture and Fukushima Prefecture, reinforcing Japan’s next-generation AI computing foundation.About eole Inceole Inc. is a publicly listed company in Japan with a rapidly growing presence in the domestic GPU server market. The company provides investment and business development support for AI data center development projects, playing an active role in advancing Japan’s AI infrastructure ecosystem.About Woodman IncWOODMAN Inc. is a Japanese technology company focusing on eliminating societal waste by transforming underutilized resources, such as surplus electricity and computing power, into new value. They specialize in constructing optimized computing environments for AI and HPC (High-Performance Computing), bridging the gap between energy infrastructure and, previously, blockchain/mining hardware.About SuperX AI Technology Limited (NASDAQ:SUPX)SuperX AI Technology Limited is an AI infrastructure solutions provider, offering a comprehensive portfolio of proprietary hardware, advanced software, and end-to-end services for AI data centers. The Company's services include advanced solution design and planning, cost-effective infrastructure product integration, and end-to-end operations and maintenance. Its core products include high-performance AI servers, 800 Volts Direct Current (800VDC) solutions, high-density liquid cooling solutions, as well as AI cloud and AI agents. Headquartered in Singapore, the Company serves institutional clients globally, including enterprises, research institutions, and cloud and edge computing deployments. For more information, please visit www.superx.sgSafe Harbor Statement This press release may contain forward-looking statements. In addition, from time to time, we or our representatives may make forward-looking statements orally or in writing. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as "may," "should," "expects," "anticipates," "contemplates," "estimates," "believes," "plans," "projected," "predicts," "potential," or "hopes" or the negative of these or similar terms. In evaluating these forward-looking statements, you should consider various factors, including: our ability to change the direction of the Company; our ability to keep pace with new technology and changing market needs; and the competitive environment of our business. These and other factors may cause our actual results to differ materially from any forward-looking statement.Forward-looking statements are only predictions. The reader is cautioned not to rely on these forward-looking statements. The forward-looking events discussed in this press release and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties, and assumptions about us. We are not obligated to publicly update or revise any forward-looking statement, whether as a result of uncertainties and assumptions, the forward-looking events discussed in this press release and other statements made from time to time by us or our representatives might not occur. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
Shanghai, January 5, 2026 - (ACN Newswire via SeaPRwire.com) – Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that it has entered into an exclusive license agreement with Shaanxi Micot Pharmaceutical Technology Co., Ltd. (“Micot”) to commercialize MT1013, the world’s first-in-class dual-targeting receptor agonist polypeptide that simultaneously targets the Calcium-Sensing Receptor (CaSR) and the Osteogenic Growth Peptide (OGP) receptor and is primarily developed with Secondary Hyperparathyroidism (SHPT) as its leading indication, in China and Asia-Pacific (excluding Japan).According to the agreement, Everest Medicines will pay Micot an upfront payment of RMB 200 million and potential regulatory and commercial milestone payments of up to RMB 1,040 million. MT1013 has entered Phase III clinical trial in China and the relevant development expenses will be covered by Micot. The strategic collaboration is expected to complement Everest Medicines’ existing renal pipeline and drive operating synergies, further strengthen the Company’s commercial product portfolio, and solidify its leading position in renal and autoimmune diseases in Asia, which are key therapeutic areas of focus. The collaboration will also expand the Company’s nephrology portfolio from IgA nephropathy to a broader range of chronic kidney diseases (CKD).MT1013 is the world’s first-in-class dual-targeting receptor agonist polypeptide internally developed by Micot. The Phase II data were presented orally and in a Late-Breaking session at the 2025 American Society of Nephrology (ASN) Annual Meeting. MT1013 uniquely combines the calcium-sensing receptor (CaSR) and the osteogenic growth peptide (OGP) receptor, addressing imbalances in parathyroid hormone (PTH), calcium, and phosphate metabolism. This innovative dual mechanism allows MT1013 to control SHPT and related bone metabolism disorders at the source, and to actively promote bone formation and repair through direct activation of osteogenic pathways, representing a therapeutic innovation shift from indirect inhibition of bone resorption to active stimulation of bone formation.Clinical studies have demonstrated that MT1013 acts rapidly, with strong and durable efficacy, and has a favorable safety profile in patients with CKD on maintenance hemodialysis with SHPT. It has shown potential advantages over current therapies in achieving comprehensive endpoints, including control of intact parathyroid hormone (iPTH), serum calcium, and phosphate levels, as well as improving calcium-phosphate balance and offering potential cardiovascular benefits. MT1013 is currently being evaluated in a Phase III clinical trial in China for this patient population, with over 50% of the target enrollment already achieved. SHPT is one of the most common and serious complications in patients with CKD. It causes disturbances in calcium and phosphate metabolism, elevated PTH levels, bone disorders, and vascular calcification, which substantially increase the risk of fractures, cardiovascular events, and mortality. SHPT is therefore an important factor influencing outcomes and prognosis in patients with CKD. With the global prevalence of CKD continuing to rise, the unmet medical need for effective SHPT therapies is also growing. Data indicate that the global population of patients with CKD has increased from 905.2 million in 2019 to 1.0655 billion in 2024 and is projected to exceed 1.2 billion by 2030 and 1.5 billion by 2035. Over the same period, the number of patients with SHPT has also continued to rise and is expected to reach approximately 189.9 million by 2030 and 221.7 million by 2035, highlighting a substantial and growing unmet medical need.“We are very pleased to collaborate with Micot. As the global burden of chronic kidney disease continues to rise, addressing patients’ unmet needs remains a top priority.,” said Mr. Yifang Wu, Chairman of the Board of Everest Medicines. “MT1013 represents an innovative asset with the potential to expand treatment options for patients with secondary hyperparathyroidism. Through this partnership, we aim to leverage our expertise in autoimmune-related kidney disorders while broadening our renal portfolio to include additional diseases, including glomerulonephritis and complications associated with dialysis. Looking ahead, we will jointly advance the development and commercialization of MT1013 to bring innovative treatment options to a broader population of patients with kidney disease.”“We are delighted to enter into this strategic collaboration with Everest Medicines. Everest’s deep expertise in nephrology and established commercialization capabilities make it an ideal partner to bring MT1013 to patients in China and beyond,” said Dr. Bing Wang, Founder, Chairman, and President of Micot. “MT1013 is a pivotal achievement of our peptide technology platform and a key milestone in our commitment to advancing innovative therapies for chronic diseases. Its unique dual-targeting mechanism has the potential to deliver meaningful advances in the treatment of secondary hyperparathyroidism. We look forward to working closely with Everest to accelerate clinical development and commercialization, address critical unmet medical needs, and advance care for patients with kidney disease.”MT1013 has completed its pivotal Phase II clinical trial, which demonstrated robust and sustained iPTH suppression in patients with SHPT undergoing maintenance hemodialysis. In head-to-head comparisons with etelcalcetide, MT1013 showed advantages in comprehensive disease management, achieving higher rates of simultaneous control of iPTH, serum calcium, and phosphate, as well as greater reductions in phosphate and the cardiovascular risk marker FGF-23. Over 52 weeks of treatment, MT1013 also resulted in significant improvements in bone mineral density and bone metabolism markers, supporting the potential clinical benefits of its unique dual-target mechanism in both disease management and bone health.Building on these positive results, the Phase II data were presented orally and in a Late-Breaking session at the 2025 American Society of Nephrology Annual Meeting. MT1013 has now advanced into a confirmatory Phase III clinical trial in China with cinacalcet as the active comparator. The Phase III study has been launched across more than 100 sites nationwide, aiming to enroll approximately 424 patients, specifically targeting individuals with SHPT undergoing maintenance hemodialysis due to chronic kidney disease.About MT1013MT1013 is the world’s first-in-class dual-targeting receptor agonist polypeptide that simultaneously targets the Calcium-Sensing Receptor (CaSR) and the Osteogenic Growth Peptide (OGP) receptor and is primarily developed with Secondary Hyperparathyroidism as its leading indication and is planned to expand into additional indications including Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) with Osteoporosis and SHPT not on Dialysis. MT1013 completed its Phase II clinical trial (MT1013-II-C01) for the treatment of SHPT in May 2025 and has entered a Phase III clinical trial using Cinacalcet as the active comparator.About Everest MedicinesEverest Medicines is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative pharmaceutical products that address critical unmet medical needs for patients in global markets. The management team of Everest Medicines has deep expertise and an extensive track record both in China and with leading global pharmaceutical companies.The Company’s therapeutic areas of focus include autoimmune, ophthalmology, critical care, and CKM (cardiovascular, kidney, and metabolic) diseases. Everest Medicines has developed a fully integrated commercialization platform that combines omnichannel commercial capabilities with end-to-end product lifecycle management. Leveraging its proprietary mRNA platform, the Company is advancing its existing pipeline, including mRNA in vivo CAR-T and mRNA cancer vaccines, while selectively expanding into additional high-value therapeutic areas with blockbuster potential, and accelerating its global expansion. For more information, please visit the Company’s website: www.everestmedicines.com.About MicotShaanxi Micot Pharmaceutical TechnologyCo., Ltd.("Micot") was founded in Xi’an in January 2007 and now operates in China (Xi’an, Suzhou, Beijing, Shanghai, Hong Kong) and the U.S. An R&D-driven innovator, Micot develops dual- and multi-functional peptide drugs for cardiovascular/cerebrovascular and metabolic diseases to address unmet clinical needs.As the proposer, implementer, validator, and developer of the bispecific peptide concept, Micot stands as a premier platform for peptide drug R&D. It utilizes a unique mechanism for screening multi-target peptide therapeutics and possesses platform-based R&D capabilities to develop both First-in-class and Best-in-class candidates.Currently, Micot has a robust reserve of new drug candidates, with seven proprietary innovative pipelines currently in clinical stage: one in Phase III, three in Phase II, and three in Phase I. Dedicated to creating breakthrough medicines and saving lives, Micot strives to address unmet clinical needs and leverages scientific innovation to safeguard human health. For more information, please visit the website: www.micot.cn.Forward-Looking StatementsThis news release may make statements that constitute forward-looking statements, including descriptions regarding the intent, belief or current expectations of the Company or its officers with respect to the business operations and financial condition of the Company, which can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “confident” and similar statements. Such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, or other factors, some of which are beyond the control of the Company and are unforeseeable. Therefore, the actual results may differ from those in the forward-looking statements as a result of various factors and assumptions, such as future changes and developments in our business, competitive environment, political, economic, legal and social conditions. The Company or any of its affiliates, directors, officers, advisors or representatives has no obligation and does not undertake to revise forward-looking statements to reflect new information, future events or circumstances after the date of this news release, except as required by law. Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com
Shanghai, January 5, 2026 - (ACN Newswire via SeaPRwire.com) – Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that it has entered into an exclusive license agreement with Shaanxi Micot Pharmaceutical Technology Co., Ltd. (“Micot”) to commercialize MT1013, the world’s first-in-class dual-targeting receptor agonist polypeptide that simultaneously targets the Calcium-Sensing Receptor (CaSR) and the Osteogenic Growth Peptide (OGP) receptor and is primarily developed with Secondary Hyperparathyroidism (SHPT) as its leading indication, in China and Asia-Pacific (excluding Japan).According to the agreement, Everest Medicines will pay Micot an upfront payment of RMB 200 million and potential regulatory and commercial milestone payments of up to RMB 1,040 million. MT1013 has entered Phase III clinical trial in China and the relevant development expenses will be covered by Micot. The strategic collaboration is expected to complement Everest Medicines’ existing renal pipeline and drive operating synergies, further strengthen the Company’s commercial product portfolio, and solidify its leading position in renal and autoimmune diseases in Asia, which are key therapeutic areas of focus. The collaboration will also expand the Company’s nephrology portfolio from IgA nephropathy to a broader range of chronic kidney diseases (CKD).MT1013 is the world’s first-in-class dual-targeting receptor agonist polypeptide internally developed by Micot. The Phase II data were presented orally and in a Late-Breaking session at the 2025 American Society of Nephrology (ASN) Annual Meeting. MT1013 uniquely combines the calcium-sensing receptor (CaSR) and the osteogenic growth peptide (OGP) receptor, addressing imbalances in parathyroid hormone (PTH), calcium, and phosphate metabolism. This innovative dual mechanism allows MT1013 to control SHPT and related bone metabolism disorders at the source, and to actively promote bone formation and repair through direct activation of osteogenic pathways, representing a therapeutic innovation shift from indirect inhibition of bone resorption to active stimulation of bone formation.Clinical studies have demonstrated that MT1013 acts rapidly, with strong and durable efficacy, and has a favorable safety profile in patients with CKD on maintenance hemodialysis with SHPT. It has shown potential advantages over current therapies in achieving comprehensive endpoints, including control of intact parathyroid hormone (iPTH), serum calcium, and phosphate levels, as well as improving calcium-phosphate balance and offering potential cardiovascular benefits. MT1013 is currently being evaluated in a Phase III clinical trial in China for this patient population, with over 50% of the target enrollment already achieved. SHPT is one of the most common and serious complications in patients with CKD. It causes disturbances in calcium and phosphate metabolism, elevated PTH levels, bone disorders, and vascular calcification, which substantially increase the risk of fractures, cardiovascular events, and mortality. SHPT is therefore an important factor influencing outcomes and prognosis in patients with CKD. With the global prevalence of CKD continuing to rise, the unmet medical need for effective SHPT therapies is also growing. Data indicate that the global population of patients with CKD has increased from 905.2 million in 2019 to 1.0655 billion in 2024 and is projected to exceed 1.2 billion by 2030 and 1.5 billion by 2035. Over the same period, the number of patients with SHPT has also continued to rise and is expected to reach approximately 189.9 million by 2030 and 221.7 million by 2035, highlighting a substantial and growing unmet medical need.“We are very pleased to collaborate with Micot. As the global burden of chronic kidney disease continues to rise, addressing patients’ unmet needs remains a top priority.,” said Mr. Yifang Wu, Chairman of the Board of Everest Medicines. “MT1013 represents an innovative asset with the potential to expand treatment options for patients with secondary hyperparathyroidism. Through this partnership, we aim to leverage our expertise in autoimmune-related kidney disorders while broadening our renal portfolio to include additional diseases, including glomerulonephritis and complications associated with dialysis. Looking ahead, we will jointly advance the development and commercialization of MT1013 to bring innovative treatment options to a broader population of patients with kidney disease.”“We are delighted to enter into this strategic collaboration with Everest Medicines. Everest’s deep expertise in nephrology and established commercialization capabilities make it an ideal partner to bring MT1013 to patients in China and beyond,” said Dr. Bing Wang, Founder, Chairman, and President of Micot. “MT1013 is a pivotal achievement of our peptide technology platform and a key milestone in our commitment to advancing innovative therapies for chronic diseases. Its unique dual-targeting mechanism has the potential to deliver meaningful advances in the treatment of secondary hyperparathyroidism. We look forward to working closely with Everest to accelerate clinical development and commercialization, address critical unmet medical needs, and advance care for patients with kidney disease.”MT1013 has completed its pivotal Phase II clinical trial, which demonstrated robust and sustained iPTH suppression in patients with SHPT undergoing maintenance hemodialysis. In head-to-head comparisons with etelcalcetide, MT1013 showed advantages in comprehensive disease management, achieving higher rates of simultaneous control of iPTH, serum calcium, and phosphate, as well as greater reductions in phosphate and the cardiovascular risk marker FGF-23. Over 52 weeks of treatment, MT1013 also resulted in significant improvements in bone mineral density and bone metabolism markers, supporting the potential clinical benefits of its unique dual-target mechanism in both disease management and bone health.Building on these positive results, the Phase II data were presented orally and in a Late-Breaking session at the 2025 American Society of Nephrology Annual Meeting. MT1013 has now advanced into a confirmatory Phase III clinical trial in China with cinacalcet as the active comparator. The Phase III study has been launched across more than 100 sites nationwide, aiming to enroll approximately 424 patients, specifically targeting individuals with SHPT undergoing maintenance hemodialysis due to chronic kidney disease.About MT1013MT1013 is the world’s first-in-class dual-targeting receptor agonist polypeptide that simultaneously targets the Calcium-Sensing Receptor (CaSR) and the Osteogenic Growth Peptide (OGP) receptor and is primarily developed with Secondary Hyperparathyroidism as its leading indication and is planned to expand into additional indications including Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) with Osteoporosis and SHPT not on Dialysis. MT1013 completed its Phase II clinical trial (MT1013-II-C01) for the treatment of SHPT in May 2025 and has entered a Phase III clinical trial using Cinacalcet as the active comparator.About Everest MedicinesEverest Medicines is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative pharmaceutical products that address critical unmet medical needs for patients in global markets. The management team of Everest Medicines has deep expertise and an extensive track record both in China and with leading global pharmaceutical companies.The Company’s therapeutic areas of focus include autoimmune, ophthalmology, critical care, and CKM (cardiovascular, kidney, and metabolic) diseases. Everest Medicines has developed a fully integrated commercialization platform that combines omnichannel commercial capabilities with end-to-end product lifecycle management. Leveraging its proprietary mRNA platform, the Company is advancing its existing pipeline, including mRNA in vivo CAR-T and mRNA cancer vaccines, while selectively expanding into additional high-value therapeutic areas with blockbuster potential, and accelerating its global expansion. For more information, please visit the Company’s website: www.everestmedicines.com.About MicotShaanxi Micot Pharmaceutical TechnologyCo., Ltd.("Micot") was founded in Xi’an in January 2007 and now operates in China (Xi’an, Suzhou, Beijing, Shanghai, Hong Kong) and the U.S. An R&D-driven innovator, Micot develops dual- and multi-functional peptide drugs for cardiovascular/cerebrovascular and metabolic diseases to address unmet clinical needs.As the proposer, implementer, validator, and developer of the bispecific peptide concept, Micot stands as a premier platform for peptide drug R&D. It utilizes a unique mechanism for screening multi-target peptide therapeutics and possesses platform-based R&D capabilities to develop both First-in-class and Best-in-class candidates.Currently, Micot has a robust reserve of new drug candidates, with seven proprietary innovative pipelines currently in clinical stage: one in Phase III, three in Phase II, and three in Phase I. Dedicated to creating breakthrough medicines and saving lives, Micot strives to address unmet clinical needs and leverages scientific innovation to safeguard human health. For more information, please visit the website: www.micot.cn.Forward-Looking StatementsThis news release may make statements that constitute forward-looking statements, including descriptions regarding the intent, belief or current expectations of the Company or its officers with respect to the business operations and financial condition of the Company, which can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “confident” and similar statements. Such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, or other factors, some of which are beyond the control of the Company and are unforeseeable. Therefore, the actual results may differ from those in the forward-looking statements as a result of various factors and assumptions, such as future changes and developments in our business, competitive environment, political, economic, legal and social conditions. The Company or any of its affiliates, directors, officers, advisors or representatives has no obligation and does not undertake to revise forward-looking statements to reflect new information, future events or circumstances after the date of this news release, except as required by law. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
